- TRADE NAME: Kisqali (Novartis)
- INDICATIONS: Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor)
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
- HALF-LIFE: 30–55 hours
- FDA APPROVAL DATE: 03/13/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Amiodarone, Bepridil, Boceprevir, Chloroquine, Clarithromycin, Conivaptan, Cyclosporine, CYP3A4 substrates, Dihydroergotamine, Disopyramide, Ergotamine, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Metformin, Methadone, Midazolam, Moxifloxacin, Ondansetron, Pimozide, Procainamide, QT prolonging drugs, Quinidine, Rifampin, Ritonavir, Rosuvastatin, Saquinavir, Simvastatin, Sirolimus, Sotalol, Strong CYP3A4 inducers and inhibitors, Tacrolimus, Voriconazole - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/09/2024
